At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 240 enrolled
Drug / intervention
Rabeprazole ER +1 moredrug
Likely dose
Rabeprazole ER 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
In Brief
A Phase 3 clinical trial evaluating Rabeprazole ER and Ranitidine for Gastroesophageal Reflux Disease (GERD). Completed, enrolled 240 participants across 4 sites.
Detailed Summary
The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease (GERD)
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedFeb 2009
Primary CompletionAug 2009
Study CompletionJan 2010
TodayJul 2026
First PostedFeb 9, 2009
Enrollment StartAug 1, 2008
Primary CompletionAug 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.4 years ago
Interventions
Rabeprazole ERdrug
50 mg capsule, taken orally, once daily for 26 weeks.
Ranitidinedrug
150 mg capsule, taken orally, twice daily for 26 weeks.